On 27 July 2020, orphan designation EU/3/20/2301 was granted by the European Commission to Bayer AG, Germany, for pegylated adrenomedullin (also known as PEG-ADM or BAY 1097761) for the treatment of acute respiratory distress syndrome.
|Disease / condition||
Treatment of acute respiratory distress syndrome (ARDS)
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.